Pharmaceutical formulations

Abstract

The present invention relates to formulations including compounds of Formula (I), or prodrug, or a pharmaceutically acceptable salt thereof.

1 - 3 . (canceled) 
     
     
         4 . The pharmaceutical tablet of  claim 14 , wherein the compound is present in an amount of about 25 mg to about 600 mg. 
     
     
         5 . The pharmaceutical tablet of  claim 14 , wherein the compound is present in an amount of about 50 mg to about 300 mg. 
     
     
         6 . The pharmaceutical tablet of  claim 14 , wherein the compound is present in an amount of about 100 mg. 
     
     
         7 . The pharmaceutical tablet of  claim 14 , wherein the compound is present in an amount of about 300 mg. 
     
     
         8 - 9 . (canceled) 
     
     
         10 . A method for treating a sodium-dependent glucose transporter mediated disorder, said method comprising administering to a patient in need thereof, the pharmaceutical tablet of  claim 14 . 
     
     
         11 . The method of  claim 10  wherein the compound is administered at a dose of from about 50 mg to about 300 mg once daily. 
     
     
         12 . The method of  claim 10  wherein the compound is administered at a dose of about 100 mg per day. 
     
     
         13 . The method of  claim 10  wherein the compound is administered at a dose of about 300 mg per day. 
     
     
         14 . An orally administrable pharmaceutical tablet comprising
 (a) a compound of Formula (I-S)   
       
         
           
           
               
               
           
         
         or a prodrug or pharmaceutically acceptable salt thereof present in an amount within the range of from about 40% to about 60% by weight; 
         (b) a diluent or filler comprising a combination of microcrystalline cellulose and lactose present in an amount within the range of from about 30% to about 50% by weight; 
         (c) at least one disintegrant in an amount within the range of from about 3% to about 10% by weight; 
         (d) at least one binder present in an amount within the range of from about 0.5% to about 5% by weight; and 
         (e) at least one lubricant present in an amount within the range of from about 0.5% to about 2% by weight; 
         wherein the % by weight is based on the weight of the tablet. 
       
     
     
         15 . The pharmaceutical tablet of  claim 14 , wherein the compound is 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene)hemihydrate. 
     
     
         16 - 17 . (canceled)